{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:28:00Z","timestamp":1787005680707,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Long-term effects on patient health-related quality of life (HRQoL) after direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) are unknown. We assessed the impact of DAA-mediated HCV clearance on HRQoL from DAA initiation to 1\u00a0year after confirmed sustained virological response at 24\u00a0weeks post-treatment (SVR24).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HRQoL was evaluated using the eight-item Short Form Health Survey (SF-8). Chronic HCV-infected patients were treated for 12\u00a0weeks with sofosbuvir-based DAAs. SF-8 was administered at baseline, treatment cessation, SVR24, and 1-year post-SVR24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 109 chronic HCV-infected patients were enrolled. The average SF-8 scores were higher than the Japanese national standard values for bodily pain (BP) and mental health at baseline and for general health at 1-year post-SVR24. None of the SF-8 scores differed significantly between baseline and 1-year post-SVR24. Regarding age, sex, liver status, and treatment regimen, the SF-8 scores at 1-year post-SVR24 were affected by only age; individuals aged\u2009&lt;\u200965\u00a0years had significantly higher physical component score (PCS), physical functioning, role physical, and BP scores than older individuals. In the multivariable analysis, only age of\u2009\u2265\u200965\u00a0years was significantly associated with influencing PCS at 1-year post-SVR24. However, no significant factors were identified for mental component score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Upon long-term assessment, although more factors trended higher than national standard values at 1-year post-SVR24 than at baseline, there were no significant changes within factors. As PCS tended to be associated with age, patients aged\u2009\u2265\u200965\u00a0years should be carefully monitored for PCS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11136-021-02874-6","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:02:53Z","timestamp":1621436573000},"page":"3501-3509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Health-related quality of life in patients with chronic hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7747-5977","authenticated-orcid":false,"given":"Akio","family":"Miyasaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"4 pt 1","key":"2874_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.1840120409","volume":"12","author":"K Kiyosawa","year":"1990","unstructured":"Kiyosawa, K., Sodeyama, T., Tanaka, E., Gibo, Y., Yoshizawa, K., Nakano, Y., et al. (1990). Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology, 12(4 pt 1), 671\u2013675","journal-title":"Hepatology"},{"issue":"9055","key":"2874_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard, T., Bedossa, P., & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. THE OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. The Lancet, 349(9055), 825\u2013832","journal-title":"The Lancet"},{"issue":"6","key":"2874_CR3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami, M., Yokosuka, O., Takehara, T., Sakamoto, N., Korenaga, M., Mochizuki, H., et al. (2015). Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-na\u00efve and previously treated Japanese patients with genotype 1 hepatitis C: An open-label randomized, phase 3 trial. The Lancet Infectious Diseases, 15(6), 645\u2013653","journal-title":"The Lancet Infectious Diseases"},{"issue":"11","key":"2874_CR4","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata, M., Nishiguchi, S., Ueno, Y., Mochizuki, H., Izumi, N., Ikeda, F., et al. (2014). Sofosubvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. Journal of Viral Hepatitis, 21(11), 762\u2013768","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"2874_CR5","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.3892\/etm.2016.3785","volume":"12","author":"M Suzuki","year":"2016","unstructured":"Suzuki, M., Ishikawa, T., Sakuma, A., Abe, S., Abe, H., Koyama, F., et al. (2016). Evaluation of the health-related quality of life using the SF-36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon\/ribavirin\/telaprevir triple treatment. Experimental and Therapeutic Medicine, 12(5), 3353\u20133358","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"2","key":"2874_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2893.2003.00482.x","volume":"11","author":"R Perrillo","year":"2004","unstructured":"Perrillo, R., Rothstein, K. D., Rubin, R., Alam, I., Imperial, J., Harb, G., et al. (2004). Comparison of quality of life, work productivity and medical resource utilization of peginterferon alfa 2a vs the combination interferon alpha 2a plus ribavirin as initial treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis, 11(2), 157\u2013165","journal-title":"Journal of Viral Hepatitis"},{"issue":"2","key":"2874_CR7","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/jgh.12337","volume":"29","author":"H Matsushita","year":"2014","unstructured":"Matsushita, H., Ikeda, F., Iwasaki, Y., Seki, H., Nanba, S., Takeuchi, Y., et al. (2014). Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavarin therapy for chronic hepatitis C. Journal of Gasteroenterology and Hepatology, 29(2), 337\u2013343","journal-title":"Journal of Gasteroenterology and Hepatology"},{"issue":"14","key":"2874_CR8","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.2169\/internalmedicine.0091-17","volume":"57","author":"M Kawakubo","year":"2018","unstructured":"Kawakubo, M., Eguchi, Y., Okada, M., Iwanes, S., Oeda, S., Otsuka, T., et al. (2018). Chronic hepatitis C treatment with daclatasvir plus asunaprevir does not lead to a decreased quality of life. Internal Medicine, 57(14), 1959\u20131966","journal-title":"Internal Medicine"},{"issue":"9","key":"2874_CR9","doi-asserted-by":"publisher","first-page":"e2702","DOI":"10.1097\/MD.0000000000002702","volume":"95","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M., Stepanova, M., Chan, H. L. Y., Lee, M. H., Yu, M. L., Dan, Y. Y., et al. (2016). Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine, 95(9), e2702","journal-title":"Medicine"},{"issue":"1","key":"2874_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12955-017-0598-8","volume":"15","author":"Z Younossi","year":"2017","unstructured":"Younossi, Z., Stepanova, M., Omata, M., Mizokami, M., Walters, M., & Hunt, S. (2017). Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-bases regimens in clinical trials. Health and Quality of Life Outcomes, 15(1), 25","journal-title":"Health and Quality of Life Outcomes"},{"issue":"33","key":"2874_CR11","doi-asserted-by":"publisher","first-page":"e4243","DOI":"10.1097\/MD.0000000000004243","volume":"95","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M., Stepanova, M., Omata, M., Mizokami, M., Walters, M., & Hunt, S. (2016). Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine, 95(33), e4243","journal-title":"Medicine"},{"key":"2874_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39, 175\u2013191","journal-title":"Behavior Research Methods"},{"key":"2874_CR13","volume-title":"How to score and interpret single-item health status measures; A manual for users of the SF-8TM health survey","author":"JE Ware","year":"2008","unstructured":"Ware, J. E., Kosinski, M., Dewey, J. E., & Gandek, B. (2008). How to score and interpret single-item health status measures; A manual for users of the SF-8TM health survey. Lincoln, RI: QualityMetric Inc."},{"key":"2874_CR14","volume-title":"Manual of the SF-8 Japanese version","author":"S Fukuhara","year":"2004","unstructured":"Fukuhara, S., & Suzukamo, Y. (2004). Manual of the SF-8 Japanese version. Kyoto: Institute for Health Outcomes and Process Evaluation Research."},{"issue":"5","key":"2874_CR15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1111\/liv.13601","volume":"38","author":"C H\u00f6ner zu Siederdissen","year":"2018","unstructured":"H\u00f6ner zu Siederdissen, C., Schlevogt, B., Solbach, P., Port, K., Conrberg, M., Manns, M. P., et al. (2018). Real-word effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. Liver International, 38(5), 834\u2013841","journal-title":"Liver International"},{"issue":"2","key":"2874_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11136-018-1992-3","volume":"28","author":"AM Buchanan-Hughes","year":"2019","unstructured":"Buchanan-Hughes, A. M., Buti, M., Hanman, K., Langford, B., Wright, M., & Eddowes, L. A. (2019). Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: A systematic literature review and meta-analysis. Quality of Life Research, 28(2), 297\u2013319","journal-title":"Quality of Life Research"},{"issue":"3","key":"2874_CR17","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1111\/hepr.12524","volume":"46","author":"A Tanaka","year":"2016","unstructured":"Tanaka, A., Kikuchi, K., Miura, R., Miura, K., Mikami, M., Aiso, M., et al. (2016). Validation of Japanese version of the chronic liver disease questionnaire for the assessment of health-related quality of life in patients with chronic viral hepatitis. Hepatology Research, 46(3), E45\u2013E50","journal-title":"Hepatology Research"},{"issue":"3","key":"2874_CR18","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1111\/hepr.12974","volume":"48","author":"T Ichikawa","year":"2018","unstructured":"Ichikawa, T., Miyaaki, H., Miuma, S., Taura, N., Motoyoshi, Y., Akahoshi, H., et al. (2018). Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals. Hepatology Research, 48(3), E232\u2013E239","journal-title":"Hepatology Research"},{"issue":"7","key":"2874_CR19","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.dld.2018.12.009","volume":"51","author":"S Fagiuoli","year":"2019","unstructured":"Fagiuoli, S., Caporaso, N., Morisco, F., Buelli, F., Gualberti, G., Saragaglia, V., et al. (2019). HepDisk \u2013 A new quality of life questionnaire for HCV patients. Digestive and Liver Disease, 51(7), 1008\u20131015","journal-title":"Digestive and Liver Disease"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11136-021-02874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-021-02874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:42:12Z","timestamp":1637221332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11136-021-02874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2874"],"URL":"https:\/\/doi.org\/10.1007\/s11136-021-02874-6","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"4 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent was obtained from all subjects for publication of this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}